Stifel Nicolaus analyst Rick Wise has maintained their bullish stance on BSX stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Rick Wise has given his Buy rating due to a combination of factors, including the optimistic outlook for Boston Scientific in 2025. The company’s CFO, Dan Brennan, expressed confidence in the firm’s innovation pipeline and financial robustness during recent investor meetings. Brennan described the initial 2025 guidance as “prudently conservative,” suggesting that the company is well-positioned to capitalize on operational leverage opportunities as the year progresses.
Furthermore, the high-growth potential of Boston Scientific’s Electrophysiology and Watchman divisions contributes to positive revenue projections, with the possibility of exceeding initial guidance. The company’s track record of surpassing its initial organic growth estimates in previous years reinforces this potential. These factors collectively underscore the attractive growth prospects for Boston Scientific, justifying Wise’s Buy rating.
In another report released today, Barclays also reiterated a Buy rating on the stock with a $118.00 price target.
Based on the recent corporate insider activity of 115 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.